0JXZ Stock Chart & Stats
€24.70
€0.10(0.38%)
At close: 4:00 PM EST
€24.70
€0.10(0.38%)
Day’s Range― - ―
52-Week Range€22.62 - €32.70
Previous CloseN/A
Volume42.14K
Average Volume (3M)9.16K
Market Cap
€1.74B
Enterprise Value€1.52B
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.6
Beta0.60
Next Earnings
Aug 10, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume4,733
30 Day Avg. Volume9,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.75Price Target Upside-7.89% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-2.8
Revenue Forecast (FY)€23.87M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and high solvency provide durable financial flexibility, allowing Galapagos to fund R&D and pursue partnerships without urgent refinancing. Improved returns on equity (~16% TTM) show the company can generate meaningful earnings from its capital base, reducing long-term solvency risk.
High And Improving MarginsSustainably high gross and operating margins reflect a favorable revenue mix and scalable cost structure. Such margin profiles support long-term profitability and reinvestment capacity, helping the company weather revenue variability while preserving the ability to fund strategic programs and partnerships.
Diversified Partnership-driven Business ModelA business model anchored in collaborations, licensing, milestone payments and selective product revenues creates recurring non-dilutive funding channels. These structural partnerships de-risk portions of development spending and provide staged funding that supports sustained R&D investment over multiple years.
Bears Say
Persistent Cash BurnConsistent negative OCF and FCF indicate the business is not self-funding and depends on reserves or external financing. Persistent cash burn limits strategic optionality, increases the chance of dilutive capital raises or reduced R&D scope, and is a material medium-term constraint on growth execution.
Revenue VolatilityUneven revenue momentum undermines predictability of future cash flows and makes long-term planning more difficult. Volatility can weaken partner and investor confidence, complicate milestone timing, and put pressure on sustaining high margin levels across cycles.
Earnings Volatility Risk Despite Strong Equity BaseHistoric earnings volatility means current strong returns and balance-sheet strength could be eroded if development setbacks occur. Reliance on equity reserves is finite; sustained volatility raises the probability of fundraising or program cuts, posing a structural governance and execution risk.
Galapagos News
0JXZ FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest share price was €22.62 and its highest was €32.70 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.74B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is Aug 10, 2026 which is in 37 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on May 06, 2026. The company reported €0.21 earnings per share for the quarter, beating the consensus estimate of -€0.815 by €1.025.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.7.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €0.21 in its last earnings report, beating expectations of -€0.815. Following the earnings report the stock price went down -4.189%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GB:0JXZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
0JXZ Stock 12 Month Forecast
Average Price Target
€22.75
▼(-7.89% Downside)
Technical Analysis
Options Prices
Currently, No data available
---